Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full...( (in thousands except ...),Health

(in thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

Pro Forma Pro Forma

2008 2007 2008 2007

(in thousands, except per share data)

Numerator:

Pro forma net income allocable to

common stockholders $5,571 $3,767 $10,578 $5,092

Denominator:

Weighted average shares of common

stock outstanding 16,380 230 16,283 214

Weighted average unvested shares of

common stock subject to repurchase (43) (52) (48) (48)

Adjustments to reflect the weighted

average effect of the assumed

conversion of convertible preferred

stock - 11,032 - 11,032

Pro forma weighted average shares of

common stock outstanding - basic 16,337 11,210 16,235 11,198

Dilutive effect of common equivalent

shares 1,175 1,548 1,272 1,547

Pro forma weighted average shares of

common stock outstanding - diluted 17,512 12,758 17,507 12,745

Pro forma net income per share:

Basic $0.34 $0.34 $0.65 $0.45

Diluted $0.32 $0.30 $0.60 $0.40

(1) As a result of the conversion of the Company's preferred stock into 11,032 shares of common stock upon completion of the Company's initial public offering in November 2007, there is a lack of comparability in the basic and diluted net income per share amounts for the periods presented above.